|MDACC Study No:||2012-0504 (clinicaltrials.gov NCT No: NCT01510184)|
|Title:||A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell Lymphoma in PET- negative Complete Remission After R-CHOP or R-CHOP-like Therapy|
|Principal Investigator:||Jason R. Westin|
|Treatment Agent:||Ibritumomab Tiuxetan ; Rituximab|
|Study Description:||The goal of this clinical research study is to learn if Zevalin (ibritumomab |
tiuxetan) and rituximab can help prevent lymphoma from coming back in patients
at least 60 years old who have already received chemotherapy for the disease,
and scans have shown that all the disease is gone. The safety of this
treatment will also be studied.
Ibritumomab tituxetan is designed to attach to lymphoma cells and destroy the
cells using a radioactive particle.
Rituximab is designed to attach to lymphoma cells, which may cause them to die.